As of November 6, 2026, Autonomix Medical, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 16, 2026, naming 1 appointment. The latest filing names Sandra Kalter, appointed (Form 8-K, September 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Autonomix Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Autonomix Medical, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Autonomix Medical, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | In | 8-K, 2026-09-16 |
Selling to them or working with them? See who runs Autonomix Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Autonomix Medical, Inc. and the records around it.
Autonomix Medical, Inc. elsewhere on the record
Watch Autonomix Medical, Inc.
Get an email when Autonomix Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Autonomix Medical, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Autonomix Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Autonomix Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Autonomix Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Autonomix Medical, Inc., with the record behind each one.
Find candidates like senior executive at Autonomix Medical, Inc.Every change, in the filing's words
Appointed: Sandra Kalter
On September 14, 2026, Autonomix Medical, Inc. (the "Company") Board of Directors (the "Board") increased the size of the Board from five to six members and appointed Sandra Kalter as an independent member of the Company's Board, effective immediately.
- From July 2005 to January 2025, Ms. Kalter served in various senior leadership positions, including most recently as Chief Regulatory Counsel and Vice-President from May 2011 to January 2025, overseeing legal strategy for global regulatory, quality, clinical, promotion and advertising and medical safety for Medtronic plc, a global medical device leader.
- Ms. Kalter has authored numerous publications in the field and won leadership and service awards both at Medtronic, Inc. and in the industry.
- Ms. Kalter served from November 2025 to April 2026 as a Strategic Advisor to iTolerance, a privately held premarket company in the Type 1 diabetes space.
- Ms. Kalter has served on various boards and committees, including AdvaMed from 2011 to 2025, where she served as a member of the Legal Committee through December 2025, Co-Chair of the Advertising and Promotion Working Group, and Co-Chair of the Off Label Working Group; Board member of the Food and Drug Law Institute from 2017 to 2020, and Breakthrough T1D (formerly JDRF) from 2016 to 2019.
- Ms. Kalter has a juris doctor from The National Law Center, George Washington University and a BSJ in Journalism from Northwestern University.
- We believe Ms. Kalter's extensive experience in the medical device industry provides her with the qualifications to serve as a director.
Tools for this story
Each opens in a new tab, filled in for Autonomix Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.